Nature:肿瘤复发是死灰复燃,还是老根新芽?

2016-01-18 MedSci MedSci原创

来自美国,加拿大等数十个研究机构组成的一个国际研究小组发现的证据表明,在髓母细胞瘤(medulloblastoma)患者体内复发的癌症与原发肿瘤并不一定是同一来源。这项研究结果发表在近日的《自然》(Nature)杂志上,该研究描述了他们利用小鼠模型开展的遗传工作,对人类肿瘤进行的全基因组测序,他们的研究发现以及研究人员认为要更好地治疗患者需要去做的事情。 研究人员了解在手术切除首次发病的肿瘤后,

来自美国,加拿大等数十个研究机构组成的一个国际研究小组发现的证据表明,在髓母细胞瘤(medulloblastoma)患者体内复发的癌症与原发肿瘤并不一定是同一来源。这项研究结果发表在近日的《自然》(Nature)杂志上,该研究描述了他们利用小鼠模型开展的遗传工作,对人类肿瘤进行的全基因组测序,他们的研究发现以及研究人员认为要更好地治疗患者需要去做的事情。

研究人员了解在手术切除首次发病的肿瘤后,形成的肿瘤在遗传上与原发肿瘤是否相同。由于在手术后都是基于原发肿瘤的遗传谱来量身定制设计治疗方法对抗新肿瘤生长,这一研究具有重要的意义。为此,研究人员利用了睡美人转座子系统在测试小鼠中诱导髓母细胞瘤形成。他们随后通过模拟给人类患者处方的典型治疗进程对此进行了追踪——大约60%的人类患者会出现肿瘤复发。研究人员从原发及复发肿瘤处采集组织样本后,进行了测序。

Genetic divergence of recurrent medulloblastoma is driven by clonal selection.
Genetic divergence of recurrent medulloblastoma is driven by clonal selection.

最终测序结果令人吃惊,在11个原发肿瘤中鉴别出了23个相同的插入位点,在复发肿瘤中鉴别出了40个相同的插入位点,然而,原发肿瘤与复发肿瘤之间的插入位点“极其地不同”。该研究小组随后对小规模的人类原发和复发肿瘤进行了全基因组测序。他们报告称在原发和复发肿瘤之间发现了“惊人”的遗传差异。这提示原发肿瘤与复发的肿瘤可能是完全不同的克隆来源。

研究人员由此认为,复发的髓母细胞瘤并非是原发肿瘤重新生长的结果,而是有可能由未被治疗靶向的一种不相关的子瘤生长而来。他们建议未来临床试验包括进一步的活组织检查应注意鉴别采用不同疗法靶向的子瘤。

关于髓母细胞瘤:

髓母细胞瘤(medulloblastoma)是首先由Bailey和Cushing命名的一种儿童后颅窝恶性胶质瘤。髓母细胞瘤的细胞形态很像胚胎期的髓母细胞,因此采用这个名称。髓母细胞是一种很原始的无极细胞。在人胚胎中仅见于后髓帆,这点与髓母细胞瘤好发于小脑下蚓部相符合。髓母细胞瘤是颅内恶性程度最高的胶质瘤。

髓母细胞瘤是在靠近颅底大脑部位形成的一种致命形式的恶性肿瘤——明显不同于其他的脑瘤,它们往往会扩散至大脑和/或脊柱的其他部位。它们尤其具有侵袭性,在手术切除后有着高复发率,令人心痛地是很多时候儿童被诊断出罹患此病。

髓母细胞瘤是颅内恶性程度最高的胶质瘤。其高度恶性表现在三个方面:①生长极其迅速;②手术不易全部切除;③肿瘤细胞有沿脑脊液产生播散性种植的倾向。主要发生于14岁以下的儿童,少数见于20岁以上者。多伦多和费城儿童医院皆报道髓母细胞瘤的发病率仅次于小脑星形细胞瘤而居儿童后颅窝肿瘤的第二位。在儿童占神经胶质瘤的10.7%,占颅内肿瘤7.6%。文献中占神经胶质瘤的6.5%~10%。平均年龄14岁,12岁以下的儿童占本肿瘤全数病人的69%,男女别比为2:1。在儿童几乎均位于小脑蚓部,突入第四脑室,甚至充满小脑延髓池。偶见于小脑半球。在成人亦多见于小脑,偶见于大脑半球,但有些学者认为诊断为大脑的髓母细胞瘤,实为神经母细胞瘤。

术后平均生存0.9年,成人的预后较儿童为好。随着近年来临床医学和基础研究的不断发展,随母细胞瘤病人的预后得到不断改善。目前多数统计5年存活率均在30%以上,最高统计达80%。个别的可生存达十年以上。Quest认为疗效的提高与术后重视对整个脑与脊髓轴进行放射治疗是分不开的。Bruce认为,最近几年来对儿童髓母细胞瘤的治疗与结果有明显的进步。他新报告的15例中仅1例死亡,且CT扫描证实无肿瘤复发的征象。髓母细胞瘤患者预后与多种因素有关。目前认为手术切除肿瘤的程度与预后密切相关。全切除可明显改善预后,Raimondi认为部分切除和单纯活检其生存率无明显差别。

术后放疗是延长生存期的重要手段,辅助化疗也有一定作用。此外患者年龄与预后也有密切关系,多数文献指出较大年龄的儿童及成人髓母细胞瘤患者的预后较好。应注意的是复发和有转移病例,其预后大大低于第一次治疗,即使使用放疗和化疗,也不会获得满意的疗效。

综上所述,影响预后的因素是多方面的。无疑,彻底切除病灶,术后辅以足够剂量的放疗,有条件配合化疗等综合治疗措施,可能会大大延长髓母细胞瘤患者的生存期和改善病人的生活质量。

原始出处:

Morrissy AS, Garzia L, Shih DJ, Zuyderduyn S, Huang X, et al.Divergent clonal selection dominates medulloblastoma at recurrence. Nature. 2016 Jan 13. doi: 10.1038/nature16478. 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (11)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-03-18 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-26 doctording1

    这篇文章有一定深度

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-26 doctording1

    是一篇不错的文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-20 doct

    该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-19 没法修改啊

    我们对原发和转移,复发的,还是没有认识清楚

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-19 忠诚向上

    好好学习

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-19 sword20000

    这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-19 Jianghuiqin

    很不错!

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1880919, encodeId=442f188091938, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Mar 18 23:01:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705584, encodeId=1e3c1e055844a, content=<a href='/topic/show?id=0f5a8288537' target=_blank style='color:#2F92EE;'>#肿瘤复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82885, encryptionId=0f5a8288537, topicName=肿瘤复发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1a4e30995147, createdName=AspirantSuo, createdTime=Thu Sep 22 15:01:00 CST 2016, time=2016-09-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59661, encodeId=4a30596617c, content=这篇文章有一定深度, beContent=null, objectType=article, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=59662, encodeId=36a7596628a, content=是一篇不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=59121683644, createdName=doctording1, createdTime=Tue Jan 26 16:39:00 CST 2016, time=2016-01-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58501, encodeId=35ac5850136, content=该结果可能还存在肿瘤细胞的变异,不一定是来源于其他子瘤啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=137, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12321678168, createdName=doct, createdTime=Wed Jan 20 11:12:00 CST 2016, time=2016-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58400, encodeId=2acd58400c5, content=我们对原发和转移,复发的,还是没有认识清楚, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0ad91681314, createdName=没法修改啊, createdTime=Tue Jan 19 18:13:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58351, encodeId=6dc35835102, content=好好学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Tue Jan 19 12:32:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58343, encodeId=1bd158343c2, content=这种发现在其他复发率较高的肿瘤是否适用,有待进一步证实。, beContent=null, objectType=article, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/ajNVdqHZLLAibgOibuZnfdFE64hJHibbD6WwEgyaXx7DtibMOSicJ6JZoLEAIdAdkhDmHWO7P7OXg2tkTicZy9libryicw/0, createdBy=aa991670466, createdName=sword20000, createdTime=Tue Jan 19 12:22:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58325, encodeId=4a7958325de, content=很不错!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20170803/IMG5982F7A3DBB3C1061.jpg, createdBy=0ba51605600, createdName=Jianghuiqin, createdTime=Tue Jan 19 08:26:00 CST 2016, time=2016-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=58288, encodeId=712e58288b6, content=good, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuK9CDibOwszLoEBg36ZXqzB5NDasNV9GTfFDmBicM1V8hUS4OtTicG3IiaFIKq4wqD23LUxORRJXqjVs/0, createdBy=00e81647535, createdName=I come, createdTime=Tue Jan 19 06:40:00 CST 2016, time=2016-01-19, status=1, ipAttribution=)]
    2016-01-19 I come

    good

    0

相关资讯

梅奥:胰腺癌术后放疗可显著降低肿瘤复发

梅奥诊所癌症中心的放射肿瘤学家Christopher Hallemeier博士发现,对胰腺癌术后患者进行放疗可降低癌症复发率,就像化疗一样,是胰腺癌患者的重要治疗方式。该研究共纳入458名胰腺癌术后患者,其中378名患者术后接受化疗和放疗,80名患者术后只接受化疗。研究数据显示,诊断后5年内,进行化疗和放疗的患者中有80%的人放疗部位、肿瘤床和淋巴结没有发现复发,而术后仅化疗组该数据为68%。此外

JAMA Neurol:多发性硬化女性能不能纯母乳喂养?

随着科学技术的发展,市面上宣称能替代母乳的奶粉等产品也是层出不穷,尽管价格贵,营养元素丰富,始终无法取代纯母乳的地位。纯母乳的好处啪啦啪啦一大堆,是人类进化史上,物竞天择适者生存的自然选择,能留下发展至今,必有其无法替代的过人之处。对于正常没有疾病的孕产妇,纯母乳喂养除了会导致乳房下垂、女性魅力指数的下降,似乎其他方面的影响是利大于弊。但是现在妊娠期有并发症或合并症的孕产妇越来越多,比如说多发性硬

Melanoma Res:皮肤自检对黑色素瘤患者很重要,但很少做到

据美国癌症协会的统计,在美国每年有超过7万人被诊断患有黑色素瘤。医生建议黑色素瘤患者定期复查并进行皮肤定期自检,以查明潜在的疾病,并将复发的新发黑色素瘤扼杀在萌芽中。但新泽西州罗格斯大学癌症研究所的研究人员认为,不到15%的黑色素瘤患者能够坚持定期复查和皮肤自检。罗格斯大学的医学副教授Elliot J.Coups及同事将研究结论发表在Melanoma Research。 176名诊断为0 到III

控制卒中后抑郁和降低血压是预防卒中复发的两大关键

高血压使再次发生卒中的风险增加,抑郁也能增加再发卒中的风险。最新研究表明,超过80%卒中幸存者高血压和抑郁并存。采取这些预防措施,预防卒中再发。了解风险研究发现,卒中或者心脏病发作的前四年,抑郁与高血压并存的幸存者再发卒中或心脏病,心衰,或者因心脏病死亡的可能性比那些血压正常,无抑郁的幸存者高83%。这么高的比率提示医生不仅应该密切监测卒中幸存者的血压而且应该筛选抑郁症患者。处理高血压医生可能已经

Fertil Steril:术后长期服用避孕药或孕激素是预防子宫内膜异位症术后复发的有效手段

    虽然手术切除子宫内膜异位症既改善疼痛,提高生育能力,复发可以进一步加剧疼痛和降低生育能力,这反过来又影响生活质量和增加个人和社会成本的。因此,防止术后复发是至关重要的。本文回顾了自20世纪90年代以来,预防子宫内膜异位症术后复发的证据。在过去的5年中,许多新的研究已经进行并表明,长期的术后药物治疗显著降低复发率。这些研究大多用循环或连续的治疗方案使用口服避孕药

Fertil Steril:子宫内膜异位症的管理方法:以问题为导向和以病人为中心

子宫内膜异位症是一个千变万化的疾病,其表现形式,相关的临床问题,和可能的治疗很多。多器官浸润深部子宫内膜异位症应该算是最严重的子宫内膜异位症的形式,是最难以治疗的,也是不确定的,不仅仅引起不孕,而且盆腔疼痛的症状会限制生活质量。现有的证据表明,子宫内膜异位症不仅是一种妇科疾病,它的影响延伸到妊娠、分娩和产后期间,这一点与以往的观点相反。老的临床宗旨认为妊娠是一种治疗子宫内膜异位症现在已表现为是一种